aTyr Pharma, Inc. (ATYR) Aligns With FDA on Phase 3 Efzofitimod Study

aTyr Pharma aligned with FDA on a global Phase 3 protocol for efzofitimod in pulmonary sarcoidosis using FVC at week 48 as the primary endpoint; study activities are expected to begin in Q4 2026 and will require additional capital.Material DetailsContext by AI AnalystThis is a mid-cycle development…